Medifast, Inc. (NYSE:MED) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. decreased its holdings in shares of Medifast, Inc. (NYSE:MED - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 146,507 shares of the specialty retailer's stock after selling 22,902 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 1.34% of Medifast worth $2,581,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of MED. JPMorgan Chase & Co. boosted its stake in Medifast by 156.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 57,455 shares of the specialty retailer's stock worth $1,100,000 after purchasing an additional 35,017 shares during the period. Wells Fargo & Company MN increased its stake in Medifast by 23.5% in the 4th quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock valued at $114,000 after buying an additional 1,227 shares during the period. Barclays PLC increased its stake in shares of Medifast by 15.1% during the fourth quarter. Barclays PLC now owns 16,194 shares of the specialty retailer's stock worth $285,000 after acquiring an additional 2,127 shares during the period. Amundi purchased a new position in shares of Medifast during the 4th quarter worth approximately $374,000. Finally, American Century Companies Inc. raised its position in Medifast by 3.4% in the fourth quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer's stock worth $4,303,000 after acquiring an additional 8,058 shares in the last quarter. Institutional investors and hedge funds own 95.51% of the company's stock.

Medifast Price Performance

NYSE:MED traded down $0.31 on Wednesday, reaching $13.64. The stock had a trading volume of 26,687 shares, compared to its average volume of 296,771. The company has a market cap of $149.86 million, a price-to-earnings ratio of 75.74 and a beta of 0.96. Medifast, Inc. has a 12-month low of $11.57 and a 12-month high of $26.53. The firm's fifty day moving average is $13.14 and its two-hundred day moving average is $15.59.

Medifast (NYSE:MED - Get Free Report) last released its earnings results on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Medifast had a return on equity of 10.64% and a net margin of 0.35%. The firm had revenue of $115.73 million during the quarter, compared to analysts' expectations of $114.85 million. As a group, research analysts forecast that Medifast, Inc. will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MED has been the topic of a number of research analyst reports. StockNews.com raised shares of Medifast from a "hold" rating to a "buy" rating in a report on Thursday, May 1st. DA Davidson reduced their target price on Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th.

Medifast Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.